Nicoletta Cieri, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 14 | 2024 | 5671 | 1.150 |
Why?
|
Immunologic Memory | 7 | 2020 | 1359 | 1.010 |
Why?
|
Transplantation, Homologous | 11 | 2024 | 4806 | 0.870 |
Why?
|
T-Lymphocytes | 9 | 2023 | 10194 | 0.610 |
Why?
|
Leukemia | 3 | 2024 | 1522 | 0.560 |
Why?
|
Myeloablative Agonists | 1 | 2015 | 209 | 0.470 |
Why?
|
Busulfan | 1 | 2015 | 258 | 0.470 |
Why?
|
Lymphopoiesis | 1 | 2015 | 133 | 0.460 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2015 | 263 | 0.440 |
Why?
|
Immunotherapy, Adoptive | 3 | 2023 | 1469 | 0.430 |
Why?
|
Cyclophosphamide | 2 | 2017 | 2218 | 0.420 |
Why?
|
Precursor Cells, T-Lymphoid | 1 | 2012 | 19 | 0.420 |
Why?
|
Transplantation Conditioning | 2 | 2018 | 1590 | 0.400 |
Why?
|
Interleukin-7 | 1 | 2012 | 143 | 0.400 |
Why?
|
Interleukin-15 | 1 | 2012 | 185 | 0.390 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2015 | 678 | 0.380 |
Why?
|
Lymphoma, B-Cell | 1 | 2015 | 940 | 0.320 |
Why?
|
Immunotherapy | 2 | 2021 | 4652 | 0.310 |
Why?
|
Gene Expression Regulation, Leukemic | 3 | 2021 | 651 | 0.300 |
Why?
|
Sirolimus | 1 | 2015 | 1533 | 0.300 |
Why?
|
Diphosphonates | 1 | 2012 | 636 | 0.280 |
Why?
|
Orthopedic Procedures | 1 | 2017 | 1265 | 0.280 |
Why?
|
Leukemia, Myeloid, Acute | 4 | 2024 | 3613 | 0.250 |
Why?
|
Genetic Engineering | 3 | 2015 | 933 | 0.240 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2012 | 1116 | 0.240 |
Why?
|
Hemorrhage | 1 | 2017 | 3424 | 0.240 |
Why?
|
T-Lymphocyte Subsets | 1 | 2012 | 1802 | 0.230 |
Why?
|
Cell Tracking | 2 | 2015 | 139 | 0.230 |
Why?
|
Antigens, Neoplasm | 2 | 2022 | 1993 | 0.220 |
Why?
|
Neoplasms | 3 | 2021 | 22170 | 0.210 |
Why?
|
Neoplasm Proteins | 3 | 2021 | 3617 | 0.210 |
Why?
|
Immunophenotyping | 2 | 2021 | 1870 | 0.210 |
Why?
|
Graft vs Host Reaction | 1 | 2021 | 102 | 0.190 |
Why?
|
Lymphocyte Transfusion | 1 | 2021 | 232 | 0.180 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2021 | 293 | 0.170 |
Why?
|
DNA, Mitochondrial | 1 | 2024 | 865 | 0.160 |
Why?
|
HLA Antigens | 2 | 2022 | 1328 | 0.160 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2021 | 2547 | 0.160 |
Why?
|
Clonal Anergy | 1 | 2019 | 170 | 0.150 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2022 | 4369 | 0.150 |
Why?
|
Monitoring, Immunologic | 1 | 2018 | 98 | 0.150 |
Why?
|
Antineoplastic Agents | 3 | 2021 | 13639 | 0.150 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2021 | 4580 | 0.140 |
Why?
|
HLA-DR Antigens | 1 | 2019 | 602 | 0.140 |
Why?
|
Substrate Specificity | 1 | 2021 | 1791 | 0.140 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2018 | 125 | 0.140 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2020 | 828 | 0.130 |
Why?
|
Immune System | 1 | 2021 | 796 | 0.130 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2015 | 85 | 0.120 |
Why?
|
Adoptive Transfer | 1 | 2017 | 819 | 0.120 |
Why?
|
Enoxaparin | 1 | 2017 | 391 | 0.120 |
Why?
|
Hospitals, Community | 1 | 2017 | 365 | 0.120 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 11742 | 0.120 |
Why?
|
Lymphocyte Activation | 2 | 2021 | 5486 | 0.110 |
Why?
|
Bone Marrow Transplantation | 1 | 2021 | 2693 | 0.110 |
Why?
|
Stem Cell Transplantation | 1 | 2021 | 1600 | 0.110 |
Why?
|
Melanoma | 2 | 2022 | 5709 | 0.110 |
Why?
|
Gene Expression Profiling | 3 | 2024 | 9420 | 0.110 |
Why?
|
Myelodysplastic Syndromes | 1 | 2023 | 1394 | 0.110 |
Why?
|
Blood Donors | 1 | 2015 | 345 | 0.100 |
Why?
|
Gene Transfer Techniques | 2 | 2017 | 1206 | 0.100 |
Why?
|
L-Selectin | 1 | 2012 | 209 | 0.100 |
Why?
|
Salvage Therapy | 1 | 2018 | 1264 | 0.100 |
Why?
|
Cell Proliferation | 4 | 2017 | 10445 | 0.100 |
Why?
|
Antigens, CD | 2 | 2019 | 4003 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3639 | 0.090 |
Why?
|
Fructose | 1 | 2013 | 288 | 0.090 |
Why?
|
Humans | 28 | 2024 | 761504 | 0.090 |
Why?
|
Transduction, Genetic | 1 | 2014 | 903 | 0.090 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 1640 | 0.090 |
Why?
|
Multiple Myeloma | 2 | 2019 | 5146 | 0.090 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1372 | 0.090 |
Why?
|
Tissue Donors | 4 | 2024 | 2331 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2021 | 1896 | 0.080 |
Why?
|
Antigen-Presenting Cells | 2 | 2023 | 964 | 0.080 |
Why?
|
Haplotypes | 1 | 2015 | 2713 | 0.080 |
Why?
|
Warfarin | 1 | 2017 | 1483 | 0.080 |
Why?
|
Killer Cells, Natural | 1 | 2017 | 2200 | 0.080 |
Why?
|
Mice, Inbred NOD | 1 | 2012 | 1827 | 0.080 |
Why?
|
Mutation | 2 | 2024 | 30052 | 0.080 |
Why?
|
Stem Cells | 1 | 2021 | 3522 | 0.080 |
Why?
|
Mice, SCID | 1 | 2012 | 2626 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2012 | 1834 | 0.070 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 2219 | 0.070 |
Why?
|
Single-Cell Analysis | 3 | 2024 | 2449 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 6310 | 0.070 |
Why?
|
Abdominal Pain | 1 | 2013 | 1071 | 0.070 |
Why?
|
Cell Differentiation | 2 | 2015 | 11528 | 0.070 |
Why?
|
Cell Survival | 2 | 2015 | 5791 | 0.070 |
Why?
|
Cytokines | 1 | 2021 | 7396 | 0.070 |
Why?
|
Cluster Analysis | 1 | 2012 | 2707 | 0.060 |
Why?
|
Phenotype | 5 | 2024 | 16591 | 0.060 |
Why?
|
Graft vs Host Disease | 2 | 2017 | 3029 | 0.060 |
Why?
|
Disease-Free Survival | 1 | 2015 | 6814 | 0.060 |
Why?
|
Bone Density Conservation Agents | 1 | 2012 | 795 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10766 | 0.060 |
Why?
|
Peptide Fragments | 1 | 2017 | 5112 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2017 | 4174 | 0.060 |
Why?
|
Lymphocyte Count | 2 | 2017 | 778 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 1 | 2020 | 3763 | 0.060 |
Why?
|
Female | 14 | 2024 | 392644 | 0.060 |
Why?
|
Recurrence | 3 | 2023 | 8465 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2017 | 1866 | 0.060 |
Why?
|
Tumor Microenvironment | 3 | 2022 | 3877 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9280 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2019 | 8547 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2022 | 5821 | 0.050 |
Why?
|
Hematopoietic Stem Cells | 1 | 2015 | 3396 | 0.050 |
Why?
|
Mice | 3 | 2021 | 81525 | 0.050 |
Why?
|
Aged | 6 | 2020 | 169289 | 0.050 |
Why?
|
Clone Cells | 2 | 2015 | 1659 | 0.050 |
Why?
|
Animals | 4 | 2021 | 168459 | 0.050 |
Why?
|
Anticoagulants | 1 | 2017 | 4812 | 0.050 |
Why?
|
Adult | 9 | 2024 | 221177 | 0.050 |
Why?
|
Migraine Disorders | 1 | 2013 | 1701 | 0.040 |
Why?
|
Middle Aged | 7 | 2024 | 220895 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2023 | 424 | 0.040 |
Why?
|
Male | 10 | 2024 | 360804 | 0.040 |
Why?
|
CD4-CD8 Ratio | 1 | 2019 | 114 | 0.040 |
Why?
|
Glucocorticoid-Induced TNFR-Related Protein | 1 | 2019 | 39 | 0.040 |
Why?
|
Receptors, KIR | 1 | 2019 | 110 | 0.040 |
Why?
|
Leukemia, Myeloid | 1 | 2021 | 694 | 0.040 |
Why?
|
Young Adult | 4 | 2020 | 59243 | 0.040 |
Why?
|
Adenine | 1 | 2022 | 987 | 0.030 |
Why?
|
Tumor Escape | 1 | 2019 | 370 | 0.030 |
Why?
|
Genes, Transgenic, Suicide | 1 | 2015 | 34 | 0.030 |
Why?
|
Plasma Cells | 1 | 2019 | 599 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1092 | 0.030 |
Why?
|
Thymidine Kinase | 1 | 2015 | 286 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2019 | 1435 | 0.030 |
Why?
|
Retrospective Studies | 3 | 2019 | 80636 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2017 | 15631 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2022 | 6132 | 0.030 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2015 | 817 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2015 | 310 | 0.030 |
Why?
|
Lymphocyte Depletion | 1 | 2015 | 602 | 0.030 |
Why?
|
Piperidines | 1 | 2022 | 1656 | 0.030 |
Why?
|
Remission Induction | 1 | 2019 | 2396 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2021 | 16981 | 0.030 |
Why?
|
Cohort Studies | 1 | 2015 | 41487 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2021 | 14605 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2019 | 2416 | 0.020 |
Why?
|
Antigens | 1 | 2015 | 1443 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2015 | 58976 | 0.020 |
Why?
|
Genotype | 1 | 2024 | 12990 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 3602 | 0.020 |
Why?
|
Bone Marrow | 1 | 2019 | 2911 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2015 | 64680 | 0.020 |
Why?
|
Interleukin-2 | 1 | 2015 | 1889 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2018 | 5247 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6766 | 0.020 |
Why?
|
Analgesics | 1 | 2013 | 1070 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2022 | 5671 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2019 | 12795 | 0.010 |
Why?
|
Time Factors | 2 | 2015 | 39967 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2021 | 11903 | 0.010 |
Why?
|
Anticonvulsants | 1 | 2013 | 1906 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2019 | 20098 | 0.010 |
Why?
|
Signal Transduction | 1 | 2019 | 23445 | 0.010 |
Why?
|
Child | 1 | 2015 | 80153 | 0.000 |
Why?
|